Teriparatide

Generic Name: Teriparatide

Brand Names: Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva

Drug Type: Biotech

Chemical Formula: -

CAS Number: 52232-67-4

Unique Ingredient Identifier: 10T9CSU89I

Background: Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic therapy. Teriparatide is used in the treatment of osteoporosis in men and women.

Indication: Teriparatide is indicated:

Associated Conditions: Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis

Associated Therapies: -

Clinical Trials

Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: teriparatide
Drug: teriparatide and raloxifene
Drug: teriparatide and alendronate

First Posted Date: 2012-02-17

Last Posted Date: 2013-01-03

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 125

Registration Number: NCT01535027

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Effect of Teriparatide on Hip Fracture Healing

Phase 3

Completed

Conditions: Femur Neck Fracture

Interventions: Drug: Placebo
Drug: Teriparatide
Dietary Supplement: Calcium supplementation
Dietary Supplement: Vitamin D supplementation

First Posted Date: 2011-11-17

Last Posted Date: 2015-04-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 122

Registration Number: NCT01473589

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

Second Study of the Effect of Teriparatide on Hip Fracture Healing

Phase 3

Completed

Conditions: Femur Neck Fracture

Interventions: Drug: Placebo
Drug: Teriparatide
Dietary Supplement: Calcium supplementation
Dietary Supplement: Vitamin D supplementation

First Posted Date: 2011-11-17

Last Posted Date: 2015-04-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 39

Registration Number: NCT01473602

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

Phase 2

Completed

Conditions: Adult Idiopathic Generalized Osteoporosis

Interventions: Drug: Saline Placebo
Drug: Teriparatide

First Posted Date: 2011-09-27

Last Posted Date: 2019-12-11

Lead Sponsor: Elizabeth Shane

Target Recruit Count: 41

Registration Number: NCT01440803

Locations: 🇺🇸
Creighton University, Omaha, Nebraska, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

A Study of Teriparatide in Japanese Osteoporosis Patients

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Aspara-CA 600 mg
Drug: Alfarol 1.0 µg

First Posted Date: 2011-09-07

Last Posted Date: 2013-01-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT01430104

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Teriparatide
Drug: calcium citrate
Drug: Vitamin D
Drug: TNF antagonist

First Posted Date: 2011-07-22

Last Posted Date: 2017-04-11

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 26

Registration Number: NCT01400516

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States

Teriparatide Treatment in Patients With Inherited Osteoporosis

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide

First Posted Date: 2011-05-25

Last Posted Date: 2015-09-29

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 6

Registration Number: NCT01360424

Locations: 🇫🇮
Department of Orthopaedics and Traumatology and Division of Endocrinology, Department of Medicine and Pediatric Endocrinology, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland